Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Share-based Compensation (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Share-based Compensation for 7 consecutive years, with $111.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 914.79% year-over-year to $111.8 million, compared with a TTM value of $732.4 million through Dec 2025, up 1336.65%, and an annual FY2025 reading of $732.4 million, up 1336.65% over the prior year.
  • Share-based Compensation was $111.8 million for Q4 2025 at Summit Therapeutics, down from $130.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $478.8 million in Q2 2025 and bottomed at $705000.0 in Q3 2023.
  • Average Share-based Compensation over 5 years is $41.1 million, with a median of $4.8 million recorded in 2021.
  • The sharpest move saw Share-based Compensation tumbled 74.8% in 2023, then soared 4218.04% in 2025.
  • Year by year, Share-based Compensation stood at $5.6 million in 2021, then tumbled by 52.7% to $2.7 million in 2022, then soared by 229.31% to $8.8 million in 2023, then grew by 25.84% to $11.0 million in 2024, then skyrocketed by 914.79% to $111.8 million in 2025.
  • Business Quant data shows Share-based Compensation for SMMT at $111.8 million in Q4 2025, $130.8 million in Q3 2025, and $478.8 million in Q2 2025.